Press Release Details

Mr. Silvestry will be focused on delivering operational excellence, achieving ambitious growth targets, and driving the company’s service culture.

SAN DIEGO, May 26, 2020— Progenity, a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced the appointment of Damon Silvestry as Chief Operating Officer (COO). With over 15 years of strategic lab and business operations experience, Mr. Silvestry will oversee key business functions with the goal of delivering operational excellence, coordinating product teams to achieve ambitious growth targets, and driving the company’s service culture.

“Damon strengthens the Progenity executive team with an established track record as a results-driven leader capable of influencing excellence in people, process, and products while sustaining focus on cost, efficiency, margin improvement, compliance, and a positive payor/customer experience,” said Harry Stylli, PhD, CEO, chairman of the board, and co-founder of Progenity. “We are focused on accelerating growth, and creating an outstanding user experience within our diagnostic offerings and therapeutic precision medicine platforms. Damon’s experience in leading organizations, scaling similar businesses whilst improving payor and customer service standards, will enable us to achieve our goal of delivering a robust pipeline of digital health solutions based on transformative innovation.”

Mr. Silvestry combines a deep understanding of the genetic testing landscape with experience managing organizational change in high-growth life science and technology companies, including roles with Natera, Miraca Life Sciences, and Dell. Most recently, Mr. Silvestry served as Senior Vice President, Operations and People Office at Natera, where he led a team of more than 350 members to deliver both genetic testing and liquid biopsy services to enable earlier detection of cancer and determine optimal treatments.

“It’s imperative that Progenity is positioned to successfully drive improvement of patient outcomes in prenatal and perinatal medicine, oncology, and gastroenterology,” said Mr. Silvestry. “I look forward to leading Progenity’s operations and client services teams through continual improvement of operational excellence.”

About Progenity

Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For more information on how Progenity is helping clinicians and patients prepare for life, please visit www.progenity.com.

Progenity Media Contact

Kate Blom-Lowery
CG Life
kblomlowery@cglife.com
(858) 457-2436

Leadership

See our full leadership team.

Learn more.